OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	46
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	43
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	32
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	31
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	26
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	21
Learning pharmacometric covariate model structures with symbolic regression networks	19
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	16
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	13
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	13
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	13
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	13
Current practices for QSP model assessment: an IQ consortium survey	13
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	12
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	12
Training the next generation of pharmacometric modelers: a multisector perspective	11
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	11
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	11
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	10
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	10
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	9
Informatics for toxicokinetics	9
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations	9
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	9
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	9

Imputation of missing clock times – application to procalcitonin concentration time course after birth	9
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	8
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	8
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	8
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods	8
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	7
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	7
From complex data to biological insight: ‘DEKER’ feature selection and network inference	7
Statistical analysis of one-compartment pharmacokinetic models with drug adherence	7
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	7
Thanks to our Reviewers of 2022!	7
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	7
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	7
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms	6
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	6
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	6
Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice	6
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	6
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	6
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	6
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	6
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	6
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	6
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	5
JPKPD October Special Issue - Commentary	5
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	5
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	5
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	5
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	5
Correction to: Modeling the acute effects of exercise on glucose dynamics in healthy nondiabetic subjects	5
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	5
Application of machine learning based methods in exposure–response analysis	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	5
Computing optimal drug dosing with OptiDose: implementation in NONMEM	4
Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection	4
Editor’s note on the themed issue: integration of machine learning and quantitative systems pharmacology	4
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	4
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	4
Population pharmacokinetic model selection assisted by machine learning	4
A series acceleration algorithm for the gamma-Pareto (type I) convolution and related functions of interest for pharmacokinetics	4
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment	4
An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy	4
Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative	4
Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?	3
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	3
Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure	3
Thanks to our reviewers 2021!	3
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models	3

External control arms for rare diseases: building a body of supporting evidence	3
In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science	3
What should patients do if they miss a dose of medication? A theoretical approach	3
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	3
Special issue: Model-informed drug development in rare diseases: connecting the dots in an information rich ecosystem	3
How drug onset rate and duration of action affect drug forgiveness	3
Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression	3
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases	3
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	3
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	2
Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases	2
Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases	2
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel	2
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	2
Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease)	2
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach	2
An industry perspective on current QSP trends in drug development	2
Should patients skip late doses of medication? A pharmacokinetic perspective	2
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	2
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	2
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies	2
The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)	2
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system	2
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model	2
Computing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM	2
Generation and application of avatars in pharmacometric modelling	2
Correction to: Abstracts for the Ninth American Conference on Pharmacometrics (ACoP9)	2
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	2
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approach	2
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs	2
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins	1
Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy	1
Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations	1
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics	1
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	1
Changes in Associate Editors at the Journal of Pharmacokinetics and Pharmacodynamics	1
A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization	1
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach	1
Physiologically-based pharmacokinetic model for 2,4-dinitrophenol	1
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate	1
A review of the physiological effects of microgravity and innovative formulation for space travelers	1
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	1
Correction: External control arms for rare diseases: building a body of supporting evidence	1
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective	1
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 2. THR-687	1
A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis	1
Fourteenth American Conference on Pharmacometrics (ACoP14) – Innovation and Diversity: Redefining Pharmacometrics	1
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	1
Leveraging large language models to compare perspectives on integrating QSP and AI/ML	1
Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC	1
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	1
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	1
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	1
Towards a comprehensive assessment of QSP models: what would it take?	1
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice	1
Optimal control for colistin dosage selection	1
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases	1